Stayble Therapeutics AB (publ)

OM:STABL Stock Report

Market Cap: SEK 22.1m

Stayble Therapeutics Valuation

Is STABL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Share Price vs Fair Value

What is the Fair Price of STABL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for STABL?

Key metric:

The above table shows the Price to Book ratio for STABL. This is calculated by dividing STABL's market cap by their current book value.
What is STABL's PB Ratio?
PB Ratio2.2x
BookSEK 9.89m
Market CapSEK 22.08m

Price to Book Ratio vs Peers

How does STABL's PB Ratio compare to its peers?

The above table shows the PB ratio for STABL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average33.5x
ODI ODI Pharma
112.6xn/aSEK 59.4m
ONCOZ OncoZenge
6.3x-14.0%SEK 77.9m
CESSA Cessatech
13.2xn/aDKK 199.5m
NEWBRY Newbury Pharmaceuticals
1.8x146.2%SEK 82.5m
STABL Stayble Therapeutics
2.2xn/aSEK 22.1m

Price to Book Ratio vs Industry

How does STABL's PB Ratio compare vs other companies in the SE Pharmaceuticals Industry?

8 CompaniesPrice / BookEstimated GrowthMarket Cap
FLERIE Flerie
0.9xn/aUS$352.26m
MOB Moberg Pharma
0.5x66.5%US$40.42m
KDEV Karolinska Development
0.2x5.8%US$24.52m
PHARM Pharmiva
0.6xn/aUS$931.42k
STABL 2.2xIndustry Avg. 2.8xNo. of Companies8PB048121620+
8 CompaniesEstimated GrowthMarket Cap
No more companies

Price to Book Ratio vs Fair Ratio

What is STABL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

STABL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.2x
Fair PB Ration/a

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/29 08:19
End of Day Share Price 2025/01/29 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Stayble Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution